Xiamen Amoytop Biotech , Ltd. EBIT

The latest EBIT for 688278.SS is $1B as of September 2026. That compares with $1B in the prior-year period — up 2.6% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside Xiamen Amoytop Biotech , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 688278.SS's EBIT moved from $1B to $1B — a 2.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Xiamen Amoytop Biotech , Ltd.'s operating scale or balance-sheet position.

Against Healthcare companies, 688278.SS currently prints $1B for EBIT, while the sector average sits near $130B. That is roughly 99.2% below the sector mean. Large gaps often invite a closer look at Xiamen Amoytop Biotech , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $1B for 688278.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting 688278.SS's EBIT ($1B), review year-over-year change from $1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.